Page 145 - Genentech News Today

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A plethora of targeted therapies, biomarker-driven therapies, and immunotherapies are now available.

Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market, By Drug, By Route of Administration, By Distribution Channel, and By...

NEW HAVEN, Conn., June 15, 2023 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon,... | June 15, 2023

CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting. Long-term follow-up of the phase 3 study is underway to determine potential advantages of the three-drug combination in other settings, researchers wrote.

/PRNewswire/ -- Valspec, a global provider of system validation and lifecycle services, was named a key partner in Genentechs Clinical Supply Center (CSC)...

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses mantle cell lymphoma research presented at ASCO Annual Meeting. Increasing interest in the development of new therapies for mantle cell lymphoma, such as chimeric antigen receptor T-cell therapy and bispecific antibodies, has been fueling research, Matasar said.

A new study by investigators from Mass General Brigham has found that a brief, simulated task of navigating a phone menu can detect the earliest changes in daily functioning in people at risk of developing Alzheimer’s disease. Investigators found that an older adult’s performance on the test, which can be completed in a matter of minutes, was associated with the hallmarks of Alzheimer’s disease pathology, including amyloid and tau depositions in the brain. The findings, which were publishe...

Rebates and discounts paid to healthcare middlemen again lowered — or slowed growth in — big drugmakers’ selling prices.